Literature DB >> 112210

Familial incidence of precipitating antibodies in von Willebrand's disease: a study of four cases.

Z M Ruggeri, N Ciavarella, P M Mannucci, A Molinari, F Dammacco, J M Lavergne, D Meyer.   

Abstract

Precipitating antibodies directed toward human F.VIII/WF were found in the plasma of four out of 17 multitransfused patients with severe, homozygous-like VWD. The familial incidence was illustrated by the development of these antibodies in three patients from the same kindred. Such antibodies, titrated with newly developed quantitative assays of anti-VIIIR:Ag and anti-VIIIR:RCo, were directed toward only these components of F.VIII/WF. VIII:C was neutralized in a time-independent manner in plasma and was not inactivated when separated from F.VIII/WF by solid-phase PE absorption. Plasma, serum, or immunoglobulin reacted in precipitation systems (immunodiffusion, EID, CIE) with human VIIIR:Ag, with some degree of cross-reactivity toward VIIIR:Ag from other mammalian plasmas. When used in IRMA, these antibodies demonstrated the same abnormalities as heterologous antisera in variant VWD: decreased binding affinity or nonparallelism of the dose-response curves. They are polyclonal IgG with both kappa and lambda light chains. It is suggested that in some patients with severe homozygous-like VWD, the synthesis of the component of F.VIII/WF carrying VIIIR:Ag and VIIIR:RCo is suppressed whereas VIII:C production is not completely abolished.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 112210

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  6 in total

Review 1.  Alport syndrome, basement membranes and collagen.

Authors:  C E Kashtan; M M Kleppel; R J Butkowski; A F Michael; A J Fish
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

Review 2.  Alloantibodies in von Willebrand disease.

Authors:  Paula D James; David Lillicrap; Pier M Mannucci
Journal:  Blood       Date:  2013-01-07       Impact factor: 22.113

3.  Gene deletions correlate with the development of alloantibodies in von Willebrand disease.

Authors:  B B Shelton-Inloes; F F Chehab; P M Mannucci; A B Federici; J E Sadler
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

4.  Combination therapy with von Willebrand factor concentrate plus recombinant factor VIII during cesarean section in a patient with type 3 von Willebrand disease and a low inhibitor titer: a case report.

Authors:  Yushi Chikasawa; Takeshi Hagiwara; Masato Bingo; Kagehiro Amano; Shigeru Kikuchi; Ayano Mitsuhashi; Keiko Shinozawa; Katsuyuki Fukutake; Ei Kinai
Journal:  Int J Hematol       Date:  2022-05-09       Impact factor: 2.319

5.  Monitoring of von Willebrand factor inhibitors in patients with type 3 von Willebrand disease using a quantitative assay.

Authors:  Connie H Miller
Journal:  Haemophilia       Date:  2021-06-05       Impact factor: 4.263

Review 6.  Current and Emerging Options for the Management of Inherited von Willebrand Disease.

Authors:  Jessica M Heijdra; Marjon H Cnossen; Frank W G Leebeek
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.